Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $8.9000 (-9.55%) ($8.8000 - $9.6000) on Wed. Apr. 1, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.92% (three month average) | RSI | 57 | Latest Price | $8.9000(-9.55%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX declines -2.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 12.9% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) XBI(64%) ARKG(58%) IBB(56%) ARKK(55%) IWO(55%) | Factors Impacting TGTX price | TGTX will decline at least -3.46% in a week (0% probabilities). VIXM(-36%) VXX(-33%) UUP(-16%) TLT(-2%) TBT(2%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.46% (StdDev 6.92%) | Hourly BBV | 0 () | Intraday Trend | -5.9% | | | |
|
Resistance Level | $9.41 | 5 Day Moving Average | $9.93(-10.37%) | 10 Day Moving Average | $9.35(-4.81%) | 20 Day Moving Average | $9.41(-5.42%) | To recent high | -44.3% | To recent low | 24.6% | Market Cap | $1.127b | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |